Department of Epidemiology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
Lung Cancer. 2011 Jun;72(3):370-7. doi: 10.1016/j.lungcan.2010.10.011. Epub 2010 Nov 13.
The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage.
To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancer patients. Primary outcomes included objective response (TR) (i.e., complete response+partial response vs. stable disease+progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard.
We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLC patients.
There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC.
核苷酸切除修复（NER）途径通过去除药物诱导的 DNA 损伤来调节铂类化疗的疗效。
为了总结已发表的关于 NER 基因与非小细胞肺癌（NSCLC）对铂类化疗反应之间关系的研究数据，我们对 17 项已发表的 ERCC1 C118T/C8092A 和 ERCC2 Lys751Gln/Asp312Asn 多态性研究进行了荟萃分析，包括 2097 名癌症患者。主要结局包括客观缓解率（TR）（即完全缓解+部分缓解与稳定疾病+进展疾病）、无进展生存期（PFS）和总生存期（OS）。我们计算了比值比（OR）或风险比（HR）及其 95%置信区间（CI）来估计风险或危害。
我们发现，NER ERCC1 C118T/C8092A 和 ERCC2 Lys751Gln/Asp312Asn 多态性均不能单独与 NSCLC 患者的客观缓解率、PFS 和 OS 显著相关。
没有证据支持将 NER ERCC1 C118T/C8092A 和 ERCC2 Lys751Gln/Asp312Asn 多态性作为 NSCLC 铂类化疗的预后预测因子。
